Merck KGaA, SpringWorks

Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Exclusive-Germany's Merck in advanced talks to acquire US biotech firm Springworks
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a report from Reuters, citing people familiar with the matter.
Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks: Reuters
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker appears to have attracted the attention of a biopharma bigwig from o | Merck KGaA is said to be in advanced talks to acquire cancer and are disease specialist SpringWorks,
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms
Merck KGaA Eyes Major Acquisition in U.S. Biotech Sector
Merck KGaA is in advanced talks to acquire U.S. drugmaker Springworks Therapeutics, potentially impacting the healthcare sector with a sizable move in its cancer treatment pipeline. Springworks' stock surged on the news.
Springworks surges as Germany's Merck KGaA said to be targeting takeover
Shares of Springworks Therapeutics (NASDAQ: SWTX) surged over 37% on Monday following reports that Germany’s Merck (NSE: PROR) KGaA is in advanced talks to acqu
SpringWorks jumps as Merck KGaA reportedly in talks to acquire company
Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker
Merck's Bold Move: Eyes on Springworks in Potential $4 Billion Acquisition
Merck KGaA is in advanced negotiations to acquire U.S.-based Springworks Therapeutics, a move that could rank among the largest pharma deals for Merck. This potential acquisition aims to boost Merck's cancer treatment pipeline amidst a challenging landscape for the German healthcare giant.
Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...